Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT03702582

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03702582
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03702582. Randomized; no masking; primary purpose prevention. Start 2019-04-30 (actual); primary completion 2023-10-01 (actual). Results posted on 2026-05-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
Acronym
NEW-AF
Condition
Stroke
Condition
Bleeding
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Warfarin
Lead sponsor
Massachusetts General Hospital (class: other)

Record details

Record id
cardio:ct-nct03702582
Content hash
fd94183819efb824c15ce1f446e12e904137e6ea8ec7c2b05b7fb6342ed5a2b5